- Home
- TSBX vs MTVA Comparison
TSBX vs MTVA Comparison
Compare TSBX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBX
- MTVA
- Stock Information
- Founded
- TSBX 2015
- MTVA 2014
- Country
- TSBX United States
- MTVA United States
- Employees
- TSBX N/A
- MTVA N/A
- Industry
- TSBX
- MTVA
- Sector
- TSBX
- MTVA
- Exchange
- TSBX Nasdaq
- MTVA NYSE
- Market Cap
- TSBX 7.7M
- MTVA 7.1M
- IPO Year
- TSBX 2023
- MTVA N/A
- Fundamental
- Price
- TSBX $0.35
- MTVA $0.68
- Analyst Decision
- TSBX Buy
- MTVA Strong Buy
- Analyst Count
- TSBX 3
- MTVA 1
- Target Price
- TSBX $4.75
- MTVA $12.00
- AVG Volume (30 Days)
- TSBX 105.2K
- MTVA 247.7K
- Earning Date
- TSBX 05-08-2025
- MTVA 05-14-2025
- Dividend Yield
- TSBX N/A
- MTVA N/A
- EPS Growth
- TSBX N/A
- MTVA N/A
- EPS
- TSBX N/A
- MTVA N/A
- Revenue
- TSBX N/A
- MTVA N/A
- Revenue This Year
- TSBX N/A
- MTVA N/A
- Revenue Next Year
- TSBX N/A
- MTVA N/A
- P/E Ratio
- TSBX N/A
- MTVA N/A
- Revenue Growth
- TSBX N/A
- MTVA N/A
- 52 Week Low
- TSBX $0.29
- MTVA $0.71
- 52 Week High
- TSBX $3.39
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- TSBX 48.62
- MTVA N/A
- Support Level
- TSBX $0.33
- MTVA N/A
- Resistance Level
- TSBX $0.37
- MTVA N/A
- Average True Range (ATR)
- TSBX 0.03
- MTVA 0.00
- MACD
- TSBX 0.00
- MTVA 0.00
- Stochastic Oscillator
- TSBX 53.92
- MTVA 0.00
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.